|Antibody Name: ||
Couto, J.R., Blank, E.W., Peterson, J.A., Kiwan, R., Padlan, E.A. and Ceriani, R.L.
"Engineering of antibodies for breast cancer Therapy: Construction of chimaeric and humanized versions of the murine monoclonal antibody BrE-3"
In "Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment" (1994) Ed. Ceriani, R.L., Plenum Press, New York pp55-59.
|Donor Antibody: ||
|Acceptor Antibody: ||
Human IgG1 | k
Tandem repeat of the polypeptide core of human breast mucin.
Cancer Research Fund of Contra Costa, CA; NIH, MD
Priorities: Preserve binding affinity and diminish immunogenicity. Basically
positional consensus approach (veneering). Many of retained residues occur in
human sequences of the same subgroup. Constructed three progressively more
All 6 VH and VL, Kabat Definition.
Not stated but 9 mouse residues left in VH and 6 in VL FRs.
Increased affinity in competition binding assays. Ruled out N-glycosylation,
since the pattern was not there, but raised the possibility of O-glycosylation
causing the increase.
Mouse myeloma cell line Sp2/0-Ag14
Chimaeric mAb established authenticity of isolated cDNAs and provided fallback
option if the humanised had failed.
|Clinical Indication: ||
Human breast cancer.